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Abstract
Chronic morphine causes the mu opioid receptor (MOR) to switch its coupling from Gi/o to Gs, resulting in excitatory signaling
via both Gasa n di t sG bc dimer. Ultra-low-dose naloxone (NLX) prevents this switch and attenuates opioid tolerance and
dependence. This protective effect is mediated via a high-affinity interaction of NLX to a pentapeptide region in c-terminal
filamin A (FLNA), a scaffolding protein interacting with MOR. In organotypic striatal slice cultures, we now show that acute
morphine induces a dose-dependent Go-to-Gs coupling switch at 5 and 15 min that resolves by 1 hr. The acute Gs coupling
induced by 100 mM morphine was completely prevented by co-treatment with 100 pM NLX, (+)NLX, or naltrexone (NTX), or
theirpentapeptidebindingsite(FLNA2561–2565),whichweshowcanactasadecoyforMORorbindtoFLNAitself.Alloftheseco-
treatments presumably prevent the MOR–FLNA interaction. Since ultra-low-dose NTX also attenuates the addictive properties
of opioids, we assessed striatal cAMP production and CREB phosphorylation at S
133. Correlating with the Gs coupling, acute
morphine induced elevated cAMP levels and a several-fold increase in pS
133CREB that were also completely blocked by NLX,
NTX or the FLNA pentapeptide. We propose that acute, robust stimulation of MOR causes an interaction with FLNA that allows
aninitially transient MOR–Gscoupling,whichrecoverswithreceptorrecyclingbutpersistswhenMORstimulationis repeatedor
prolonged. The complete prevention of this acute, morphine-induced MOR–Gs coupling by 100 pM NLX/NTX or 10 mM
pentapeptide segment of FLNA further elucidates both MOR signaling and the mechanism of action of ultra-low-dose NLX or
NTX in attenuating opioid tolerance, dependence and addictive potential.
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Introduction
Ultra-low-dose opioid antagonists have been shown to enhance
opioid analgesia, minimize opioid tolerance and dependence [1,2]
and attenuate the addictive properties of opioids [3,4]. Early
electrophysiology data suggested that ultra-low-dose opioid antag-
onists block excitatory signaling of opioid receptors [1]. Chronic
opioid-induced excitatory signaling is mediated by a switch in G
protein coupling by MOR from Gi/o to Gs proteins [5,6] and by
stimulation of adenylyl cyclase II and IV by the Gbc dimer [5,7]
originatingfromthe MOR-associatedGsprotein[8].Ultra-low-dose
NLX co-treatment suppresses opioid tolerance and dependence by
preventing these MOR signaling alterations [5], and we recently
identified the NLX binding site that mediates its protective effects as
a pentapeptide segment in c-terminal FLNA [9].
A scaffolding protein best known for its actin-binding and cell
motility function, FLNA also regulates cell signaling by interacting
with a variety of receptors and signaling molecules [10,11].
Onoprishvili et al. [12] first showed FLNA to interact with MOR
and suggested a role in MOR downregulation and desensitization.
Also implicating FLNA in desensitization, our recent organotypic
striatal slice culture data showed that potentially disrupting the
MOR–FLNA interaction via NLX’s high-affinity binding to
FLNA blocks the chronic morphine-induced G protein coupling
switch by MOR [9]. Specifically, FLNA peptide fragments
containing the NLX binding site blocked the protective effect of
NLX on both the MOR–Gs coupling and downstream cAMP
accumulation induced by chronic morphine (twice daily 1-hr
exposures for 7 days), presumably by interfering with NLX’s
binding to FLNA in the tissues.
Again using organotypic striatal slice cultures, we show here
that acute morphine causes a dose-dependent and transient
MOR–Gs coupling that resolves by 1 hr. This is the first
indication that MOR–Gs coupling occurs acutely and dynamically
and is not only a consequence of chronic opioid treatment. To
assess the involvement of FLNA in this acute opioid-induced Gs
coupling, we co-treated slices with NLX, naltrexone (NTX), or
FLNA2561–2565, their pentapeptide binding site, as a decoy for
MOR. We also examined the effects of these treatments on cAMP
production and downstream phosphorylation of the cAMP-
response-element-binding protein (CREB) at S
133 as a marker of
addictive processes, since ultra-low-dose NTX attenuates the acute
rewarding effects of opioids [3,4]. CREB is activated by
phosphorylation at S
133 predominantly by protein kinase A
(PKA) through binding of cAMP. Hence, increasing levels of
cAMP from activation of adenylyl cyclase following MOR–Gs
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properties of opiates. A partial mediation of the acute rewarding
effects of opiates by Gs signaling could explain the apparent
discrepancy that ultra-low-dose NLX or NTX can enhance opioid
analgesia while also attenuating the addictive properties of opioids.
Methods
Animals
Male Sprague Dawley rats (200 to 250 g) purchased from
Taconic (Germantown, NY) were housed two per cage and
maintained on a regular 12-hr light/dark cycle in a climate-
controlled room with food and water available ad libitum. For
organotypic brain slice cultures, rats were sacrificed by rapid
decapitation and striata were removed on ice and treated in vitro as
described below. All procedures in this protocol are in compliance
with the City College of New York IACUC on the use and care of
animals.
Organotypic striatal slice cultures
Rat brain slice organotypic culture methods were modified from
those published previously [13,14]. Striatal slices (200 mm thick)
were prepared using a McIlwain tissue chopper (The Mickle
Laboratory Engineering Co., Surrey, UK) at 4uC. Slices were
immediately transferred to sterile, porous culture inserts (0.4 mm,
Millicell-CM), using the rear end of a glass Pasteur pipette. Each
culture insert unit contained 2 slices and was placed into one well
of the 12-well culture tray. Each well contained 1.5 ml of culture
medium composed of 50% MEM with Earl’s salts, 2 mM L-
glutamine, 25% Earl’s balanced salt solution, 6.5 g/l D-glucose,
20% fetal bovine serum (FBS), 5% horse serum, 25 mM HEPES
buffer and 50 mg/ml streptomycin and 50 mg/ml penicillin. The
pH was adjusted to 7.2 with HEPES buffer. Cultures were first
incubated for 2 days to minimize the impact of injury from slice
preparation. Incubator settings were 36uC with 5% CO2.
Determination of MOR–G protein coupling
To determine the dose-response of acute morphine on MOR–G
protein coupling, slices were exposed to 0.1, 1, 10 or 100 mM
morphine for 15 min. To assess the effect of ultra-low-dose NLX or
NTX on the signaling switch induced by 100 mM morphine, some
slices were exposed to 100 mM morphine plus 100 pM NLX or
NTX. To determine whether NLX’s effect may be mimicked by the
site on FLNA that interacts with MOR, brain slices were incubated
with morphine plus 10 mM VAKGL (FLNA2561–2565)o rc o n t r o l
pentapeptide, VAAGL. Peptides were purchased from Sigma-
Genosys (The Woodlands, TX). A separate experiment was
performed to assess the effect of 100 pM (+)NLX, the stereoisomer
of NLX that is inactive at MOR. Slices were exposed to (+)NLX or
(+)NLX plus 100 mM morphine for 15 and 60 min. Prior to
treatments, culture medium was removed and the culture insert
containing the slices was gently rinsed twice with warm (37uC) PBS
(pH7.2) before incubation in 0.1% FBS-containing culture medium
for 2 hr. Slices were transferred to fresh 0.1% FBS-containing
culture medium with indicated agents. Tissues were harvested 5, 15
or 60 min after drug exposures by centrifugation. To determine of
MOR–G protein coupling, slices were homogenated to generate
synaptic membranes and cytosolic fractions. Synaptic membranes
(400 mg) were solubilized with 0.5% digitonin/0.2% sodium
cholate/0.5% NP-40 in 250 ml of immunoprecipitation buffer
(25 mM HEPES, pH7.5; 200 mM NaCl, 1 mM EDTA, 50 mg/
ml leupeptin, 10 mg/ml aprotinin, 2 mg/ml soybean trypsin
inhibitor, 0.04 mM PMSF and a mixture of protein phosphatase
inhibitors). Following centrifugation, striatal membrane lysates were
immunoprecipitated with immobilized anti-Gas/olf or -Gao
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) conjugated
with immobilized protein A-agarose beads (Pierce-Endogen). The
level of MOR in anti-Gas/olf or -Gao immunoprecipitates was
determined by Western blotting using specific anti-MOR antibodies
(Santa Cruz Biotechnology).
Determination of cAMP accumulation
To measure the MOR-mediated increase in cAMP production,
brain slices were incubated with Kreb’s-Ringer (basal), 100 mM
morphine and/or co-treatment with 100 pM NLX, NTX or
10 mM VAKGL (FLNA2561–2565 ) for 5, 15 and 60 min in the
presence of 100 mM phosphodiesterase inhibitor, IBMX. For the
60-min timepoint, IBMX was added 15 min after morphine
exposure. For the experiment that assesses cAMP production by
Go-coupled MOR, slices were incubated with morphine, mor-
phine plus 10 mM VAKGL, or 10 mM VAKGL for 5 or 60 min
prior to incubation for 5 min with 10 mM forskolin. The reaction
was terminated by placing slices in ice-cold Ca
2+-free Kreb’s-
Ringer containing 0.1 mM EDTA and centrifugation. Tissues
were homogenized by sonication and protein precipitated with 1M
TCA and the supernatant obtained after centrifugation was
neutralized using 500 mM Tris, pH9.0. The level of cAMP in
brain lysates was measured by a cAMP assay kit (PerkinElmer Life
Science, Boston) according to manufacturer’s instructions.
Determination of CREB activation
To assess whether acute high-dose morphine induces CREB
activation and whether co-treatment with 100 pM NLX, NTX or
the FLNA pentapeptide alter it, the level of protein kinase A-
phosphorylated CREB, pS
133-CREB, was assessed in cytosolic and
nucleus fractions generated as described above from striatal slices.
CREB in the solubilized cytosol and nucleus was immunoprecip-
itated with immobilized anti-CREB antibodies (Santa Cruz
Biotechnology) and the level of pS
133-CREB determined by
Western blotting using a specific antibody directed against pS
133-
CREB (Santa Cruz Biotechnology).
Since CREB phosphorylation at the S
133 can also be induced in
response to elevated intracellular Ca
2+, experiments were designed
to assess the contribution of Ca
2+ by including cell permeable
intracellular Ca
2+ chelator, BAPTA-AM. In this study, striatal slice
cultures were treated with 100 mM BAPTA-AM for 30 min in
serum-free medium prior to incubation with 100 mM morphine
with or without 100 pM NLX, 100 pM NTX or 10 mM VAKGL
pentapeptide. pS
133-CREB levels in the solubilized cytosol and
nucleus were measured as described above.
Assessment of VAKGL peptide binding to MOR and FLNA
proteins
To elucidate whether the pentapeptide FLNA fragment
VAKGL functions as a MOR decoy by binding to MOR or
interacts with full-length FLNA, we utilized a cell-free system.
VAKGL biotinated at either n- or c-terminus (0.5 mg/well) was
coated onto streptavidin-coated plates (Reacti-Bind
TM NeutrAvi-
din
TM High binding capacity coated 96-well plate, Pierce). Each
condition had 12 replicates. After 3 washes with 200 ml PBS,
immunoaffinity-purified FLNA (0.5 mg) from rat brain and A7
cells or MOR (0.1 mg) from rat brain or SK-N-MC cells were
added into designated wells and incubation was carried out for
1h ra t2 5 uC with constant shaking. The plate was washed with
PBS three times and the bound FLNA and MOR detected using
anti-FLNA and -MOR antibodies followed by FITC-conjugated
anti-mouse and -rabbit IgG, respectively. Following three washes
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multi-mode plate reader (DTX-880, Beckman). The background
FITC signal from matched wells, defined by the signal produced
by unconjugated secondary antibodies at 100-fold higher dilution,
was subtracted from the total signal. This background FITC signal
was ,15% of total signal in test wells.
Data Analysis
All data are presented as mean6standard error of the mean.
Treatment effects were evaluated by two-way ANOVA followed
by Newman-Keuls test for multiple comparisons. Two-tailed
Student’s t test was used for post hoc pairwise comparisons. The
threshold for significance was p,0.05.
Results
Acute morphine induces dose-dependent MOR–Gs
coupling
After 15-min incubation with 0.1, 1, 10 or 100 mM morphine,
some MOR–Gs coupling was noted in response to 0.1 mM
morphine. With increasing dose, the Gs coupling progressively
increased as the level of Go coupling decreased (Fig. 1). While a
true comparison of the levels of Gs vs. Go coupling cannot be
made since the antibodies detecting Gas vs. Gao may have
different affinities, the progressive switch from Go to Gs coupling
at 15 min of exposure to increasing doses of morphine is clearly
visible. Additionally, although the anti-Gas/olf antibody does not
distinguish between these functionally similar Gs family members,
the Ga protein detected here in striatum may be predominantly
Golf[15].
Acute morphine-induced G protein coupling switch
blocked by 100 pM NLX/NTX or 10 mM FLNA
pentapeptide
An acute morphine-induced Go-to-Gs coupling switch in
striatal slice cultures was blocked by co-exposure to 100 pM
NLX or NTX or 10 mM concentration of their pentapeptide
binding site on FLNA (Fig. 2). Morphine (100 mM) caused a
complete Go-to-Gs coupling switch by MOR at 5 and 15 min of
exposure. After 60 min of morphine exposure, the switch had
Figure 1. Acute morphine causes a dose-dependent MOR – G protein coupling switch. Densitometric quantitation (B) of blots (A) shows
that the level of MOR–Gs coupling after 15-min morphine exposure increases progressively as dose increases from 0.1 to 100 mM concentrations. In
parallel, the level of MOR–Go coupling decreases with increasing morphine concentration. n=4. *p,0.01 compared to respective Go or Gs/olf
coupling of vehicle condition.
doi:10.1371/journal.pone.0004282.g001
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100 pM NLX or NTX prevented this acute G protein coupling
switch by MOR (Fig. 2B). Similarly, pre-treatment with the
pentapeptide binding site of NLX or NTX on FLNA (VAKGL;
FLNA2561–2565)a t1 0 mM concentration also completely pre-
vented this acute morphine-induced coupling switch by MOR
(Fig. 2B). The control peptide, FLNA2561–2565 with one mid-
point lysine-to-alanine substitution (VAAGL), did not prevent
the MOR–Gs coupling, but mildly preserved Go coupling at
15 minutes. Exposure to NLX, NTX or either peptide alone
without morphine had no effect on MOR coupling. In sum, the
only significant differences compared to the vehicle condition for
both Go and Gs coupling were the 5 and 15 minute timepoints
for both morphine and morphine + the control peptide
(VAAGL) (p,0.01 for each).
(+)NLX also blocks acute morphine-induced MOR–Gs
coupling
The naloxone isomer that is inactive as an opioid antagonist,
(+)NLX, was used to confirm that the blockade of MOR–Gs
coupling occurs by a mechanism other than antagonism of MOR.
Similar to the blockade by a 100 pM concentration of the active
isomer of NLX seen in Fig. 2, 100 pM (+)NLX blocked the Gs
coupling induced by 15 min of 100 mM morphine (Fig. 3).
NLX/NTX or the FLNA pentapeptide block acute
morphine-induced cAMP production and CREB activation
Since 100 mM morphine induced a complete Go-to-Gs switch
(Figs 1 and 2), we determined whether cAMP production is
elevated in response. As expected, acute 100 mM morphine
significantly increased cAMP levels at 5 and 15 min (Fig. 4A). This
acute morphine effect was blocked by co-treatment with 100 pM
NLX or NTX (Fig. 4A). Similarly, VAKGL but not the control
peptide VAAGL at 10 mM concentration also completely
prevented this acute morphine-induced cAMP elevation (Fig. 4A).
Exposure to NLX, NTX or either peptide alone without morphine
had no effect on cAMP levels. As with the morphine-induced Go-
to-Gs switch, cAMP differed from vehicle control only for
morphine and morphine+the control peptide (VAAGL) at the 5-
and 15-min timepoints (p,0.01 for each). To demonstrate that
MOR returns to Go coupling and inhibition of cAMP accumu-
lation at 60 min, we performed a separate experiment using
forskolin-stimulated cAMP production. With 10 mM forskolin
added to each condition for 5 min, the inhibition of cAMP after
60 min of morphine exposure was visible (Fig. 4B), illustrating that
the increased cAMP is not merely a result of desensitization of
MOR with this high dose of morphine.
To further investigate this Gs-mediated activation of adenylyl
cyclase by acute high-dose morphine (100 mM), we measured the
potential downstream activation of CREB by its phosphorylation at
serine-133. Morphine increased pS
133CREB with a timecourse that
paralleled that of the Gs coupling and cAMP accumulation (Fig. 5).
A robust level of pS
133CREB was detected in striatal tissue from slice
cultures after 5 and 15 min of morphine exposure, while only a
residual level was detected at 1 hr. Co-treatment with 100 pM NLX
or NTX, or pre-treatment with 10 mM of the VAKGL pentapep-
tide, the binding site of NLX or NTX on FLNA (FLNA2561–2565),
virtually abolished this signal. In contrast, pre-treatment with the
control peptide VAAGL did not significantly diminish pS
133CREB
levels seen in the morphine only condition. Treatment alone with
NLX,NTXoreitherpeptidedid not resultinpS
133CREBdetection.
Again, only morphine and morphine+the control peptide produced
significant differences compared to the vehicle condition (p,0.01 for
5- and 15-min timepoints and p,0.05 for 60 min).
Because phosphorylation of CREB at S
133 can also be achieved
through elevation of Ca
2+, we assessed the contribution of cAMP
and Ca
2+ to acute high-dose morphine-induced pS
133CREB by
inclusion of the cell permeable Ca
2+ chelator, BAPTA-AM.
Removal of Ca
2+ did not affect the ability of morphine to increase
pS
133CREB or the blockade of this effect by NLX, NTX or
VAKGL (Fig. 6). These data suggest that acute high-dose
morphine increases pS
133CREB mainly through the cAMP and
protein kinase A pathway.
VAKGL binding to MOR or FLNA proteins
We last investigated whether the VAKGL pentapeptide is
binding to MOR or full-length FLNA to prevent, in a manner
similar to ultra-low-dose NLX, MOR’s Gs coupling, the increased
cAMP accumulation and the CREB activation following acute
high-dose morphine. FLNA and MOR purified from two different
sources each were tested for binding to VAKGL-coated plates and
detected with anti-MOR or anti-FLNA antibodies followed by
FITC-labelled secondary antibodies. Both MOR and FLNA
bound VAKGL-coated plates (Fig. 7), suggesting that the VAKGL
pentapeptide may disrupt the MOR–FLNA interaction by binding
to MOR as a decoy for FLNA and/or by binding to FLNA itself.
Discussion
Preferentially coupling to pertussis toxin-sensitive G proteins Gi
and Go to inhibit the adenylyl cyclase/cAMP pathway (Laugwitz
et al., 1993;Connor and Christie, 1999), MOR switches to Gs
coupling after chronic opioid administration, resulting in excit-
atory signaling by both Gas and Gbc subunits [5,6,8]. Ultra-low-
dose NLX co-treatment prevents this chronic opioid-induced G
protein coupling switch and the instatement of Gbc interacting
with adenylyl cyclase, as well as the associated opioid tolerance
and dependence [5]. Although the molecular pharmacology
demonstrations of MOR–Gs coupling have used morphine, it is
reasonable to assume that a variety of opioid agonists may
similarly induce MOR–Gs coupling since ultra-low-dose NLX or
NTX have been shown to enhance and prolong analgesia and
prevent tolerance and dependence [1,2,16,17], and attenuate
addictive properties [3,4] of oxycodone as well as morphine. While
some level of Gs coupling has been previously detected in opioid-
naı ¨ve or acute morphine exposed CHO cells [6], the present work
in organotypic striatal slice cultures is the first to demonstrate that
acute exposure to a high concentration of morphine causes
predominant but transient MOR–Gs coupling similar to the
persistent change following chronic morphine. This transient and
dose-dependent G protein coupling switch of MORs, evident at 5
and 15 minutes of morphine exposure, is unlikely to represent an
acute tolerance/dependence effect since MOR had completely
reverted to its native Go coupling by 1 hour of morphine exposure.
Instead we propose that with even this brief period of continued
Figure 2. The Go-to-Gs coupling switch is transient and blocked by FLNA pentapeptide or 100 pM NLX/NTX. After 5, 15 or 60 min of
drug treatment, striatal membranes were solubilized and immunoprecipitated with immobilized anti-Ga prior to detection with anti-MOR by Western
blotting. Densitometric quantitation (B) of blots (A) shows the acute morphine-induced Go-to-Gs/olf coupling switch at 5 and 15 min timepoints that
is prevented by co-treatment with 100 pM NLX or NTX or pre-treatment with the FLNA2561–2565 pentapeptide (VAKGL), but not the control
pentapeptide (VAAGL). n=4.*p,0.01 compared to respective Go or Gs/olf coupling of vehicle condition.
doi:10.1371/journal.pone.0004282.g002
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to Gs instead of Gi/o but is able to recover. With the repeated or
prolonged MOR stimulation of chronic opiate exposure, however,
this dynamic cycling from Gs back to Go evidently becomes
impaired, leading to a persistent Gs coupling, behaviorally
manifest as opioid analgesic tolerance and dependence.
Similar to ultra-low-dose NLX’s suppression of the chronic
morphine-induced coupling switch, the present data show that this
acute morphine-induced coupling switch by MOR can be
completely prevented by co-treatment with 100 pM NLX or
NTX or 10 mM concentration of their pentapeptide binding site
on FLNA. In addition, the equal efficacy in blocking this Gs
coupling of 100 pM (+)NLX, the isomer that is inactive as an
opioid antagonist, further confirms a mechanism of action other
than antagonism of MOR. We previously discerned the precise
binding site of NLX as FLNA2561-2565 using overlapping peptides
and then blocked the protective effects of NLX on MOR–Gs
coupling and cAMP accumulation in organotypic striatal slice
cultures by co-incubation with decapeptides containing this
binding site [9]. In this prior study, FLNA peptides presumably
bound to NLX, blocking its prevention of the morphine-induced
MOR–Gs coupling by preventing it from binding full-length
FLNA in the tissues. These data led us to postulate that the
interaction between MOR and FLNA, first demonstrated by
Onoprishvili et al. (2003), was critical to the G protein coupling
switch. We theorized that a particular FLNA–MOR interaction
enables MOR to release from the signaling complex to couple to
Gs upon subsequent receptor stimulation. In addition to FLNA,
MOR has recently been shown to interact with another scaffolding
protein, spinophilin (Charlton et al., 2008). While blocking the
MOR–FLNA association, at least via ultra-low-dose NLX/NTX,
diminishes tolerance, dependence and the rewarding effects of
opiates, preserving or enhancing MOR’s association with
spinophilin appears to similarly modify these opioid effects.
In the present study, we showed the pentapeptide FLNA2561–2565
itself may act as a decoy for MOR to prevent the MOR–FLNA
Figure 3. (+)NLX also blocked the transient Go-to-Gs coupling switch induced by acute high-dose morphine. After 15 or 60 min of drug
treatment, striatal membranes were solubilized and immunoprecipitated with immobilized anti-Ga prior to detection with anti-MOR by Western
blotting. Densitometric quantitation (B) of blots (A) shows that the inactive isomer of NLX, (+)NLX, blocks the acute morphine-induced Go-to-Gs
coupling switch at 100 pM similar to NLX or NTX or pre-treatment with the VAKGL pentapeptide in fig. 2. n=4.*p,0.01 compared to respective Go
or Gs coupling of vehicle condition.
doi:10.1371/journal.pone.0004282.g003
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VAKGL pentapeptide was as effective as NLX or NTX as all
three completely blocked the transient switch to Gs coupling by
MOR during acute, high-dose morphine exposure. NLX and
NTX presumably prevent the MOR–FLNA interaction by
binding to their VAKGL binding site on FLNA, and this
binding site on FLNA does appear be the approximate site on
this protein that interacts with MOR. The demonstration that
both purified MOR and FLNA proteins bind to VAKGL
suggests that the VAKGL pentapeptide can similarly prevent
the MOR–FLNA interaction but by binding to either protein. It
is also possible that NLX and NTX block MOR–Gs coupling
by changing the conformation of FLNA upon binding rather
than by direct interference, and that by binding to ‘‘itself’’ in
the full-length protein, VAKGL similarly prevents the changed
FLNA conformation. Finally, since the VAKGL peptide can
both prevent NLX’s protective effects as in our prior study
(Wang et al., 2008) as well as mimic NLX’s protective effects
Figure 4. VAKGL or 100 pM NLX/NTX block an increased cAMP accumulation that parallels the coupling switch. A: Without stimulation
by forskolin, the morphine-induced increase in cAMP accumulation was greatest in striatal slice cultures treated with morphine for 5 or 15 min but
was still visible at 60 min. This increase was blocked by all co-treatments except the control peptide VAAGL. B: With forskolin stimulation, morphine
increased cAMP accumulation at 15 min but decreased it at 60 min, indicating a reversion back to Go coupling. The VAKGL peptide again blocked the
morphine-induced increase in cAMP accumulation. n=4. **p,0.05; *p,0.01 compared to Kreb’s-Ringer at the respective timepoint. #p,0.01
comparing VAKGL+morphine to morphine.
doi:10.1371/journal.pone.0004282.g004
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Western blots (A) shows the activation of CREB, measured by pS
133CREB detection, at 5 and 15 min of morphine exposure and its blockade by co-
treatment with 100 pM NLX or NTX or pre-treatment with the VAKGL but not the VAAGL pentapeptide. n=4.*p,0.01 and **p,0.05 compared to
vehicle.
doi:10.1371/journal.pone.0004282.g005
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pentapeptide preferentially binds NLX but in its absence will
interact with MOR or full-length FLNA. Further study is
needed to elucidate the precise VAKGL interaction site on
FLNA and MOR.
Our finding that all three co-treatments, NLX, NTX or the
decoy pentapeptide also prevented morphine-induced CREB
activation (as indicated by ser
133 phosphorylation) in these striatal
slice cultures may offer a mechanistic explanation for the
attenuation of opioid reward and addictive processes by ultra-
low-dose NTX. Found in all cells of the brain, CREB is a
transcription factor implicated in addiction as well as learning and
memory and several other experience-dependent, adaptive (or
maladaptive) behaviors [18]. In general, CREB is inhibited by
Figure 6. The calcium chelator BAPTA-AM did not notably diminish morphine-induced CREB activation or alter co-treatment
effects. Densitometric quantitation (B) of Western blots (A) shows the activation of CREB, measured by pS
133CREB detection, at 5 and 15 min of
100 mM morphine exposure and its blockade by co-treatment with 100 pM NLX or NTX or pre-treatment with the VAKGL but not the VAAGL
pentapeptide. n=4.*p,0.01 and **p,0.05 compared to vehicle.
doi:10.1371/journal.pone.0004282.g006
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chronic opioid treatment, and activated during opioid withdrawal
[19]. However, a regional mapping study showed that opioid
withdrawal activates CREB in locus coeruleus, nucleus accumbens
and amygdala but inhibits CREB in lateral ventral tegemental
area and dorsal raphe nucleus [20]. In the striatum, CREB
activation has been viewed as a homeostatic adaptation,
attenuating the acute rewarding effects of drugs [21,22]. This
view is supported by nucleus accumbens overexpression of CREB
or a dominant-negative CREB mutant respectively reducing or
increasing the rewarding effects of opioids in the conditioned place
preference test [23]. In conflict, however, reducing nucleus
accumbens CREB via antisense attenuated cocaine reinforcement
as assessed in self-administration [24]. Clearly, CREB activation is
implicated in addiction, but whether it directly contributes to the
acute rewarding effects of drugs or initiates a homeostatic
regulation thereof appears less clear.
Again, it is possible that the several-fold increase in pS
133CREB
observed here following acute, high-dose morphine might indicate
acute dependence rather than acute rewarding effects; however,
the transient nature of the MOR–Gs coupling and the return to
inhibition of cAMP at 1 hr suggests otherwise. The correlation of
pS
133CREB with the MOR–Gs coupling and cAMP production
following acute high-dose morphine exposure, as well as the
similar treatment effects on all, suggest that this alternative
signaling mode of MOR may contribute to the acute rewarding or
addictive effects of opioids. This counterintuitive notion may
explain the apparent paradox that ultra-low-dose NTX, while
enhancing the analgesic effects of opioids, decreases the acute
rewarding or addictive properties of morphine or oxycodone as
measured in conditioned place preference or self-administration
and reinstatement paradigms [3,4]. If one considers analgesic
tolerance, opioid dependence, and opioid addiction together as
adaptive regulations to continued opioid exposure, a treatment
that prevents MOR’s signaling adaptation of switching its G
protein partner may logically attenuate these seemingly divergent
behavioral consequences of chronic opioid exposure. However,
the acute rewarding effects of opioids are not completely blocked
by ultra-low-dose opioid antagonists, suggesting that a MOR–Gs
coupling may only partially contribute to the addictive or
rewarding effects. Although ultra-low-dose NTX blocks the
conditioned place preference to oxycodone or morphine [3], its
co-self-administration only reduces the rewarding potency of these
opioids but does not abolish self-administration outright [4].
Nevertheless, it is tempting to theorize that a direct stimulatory
effect on VTA neurons, as opposed to the proposed disinhibition
via inhibition of GABA interneurons [25], may play some role in
opioid reward. Finally, a MOR–Gs coupling mediation of reward,
increasing with increasing drug exposure, is in keeping with
current theories that the escalation of drug use signifying drug
dependence may not indicate a ‘‘tolerance’’ to rewarding effects
but instead a sensitization to rewarding effects [26].
In summary, the present work has demonstrated that acute,
high-dose morphine causes an immediate but transient switch in
G protein coupling by MOR from Go to Gs similar to the
persistent switch caused by chronic morphine. Ultra-low doses of
NLX, NTX or even (+)NLX prevent this switch, just as ultra-
low-dose NLX has previously been shown to attenuate the
chronic morphine-induced coupling switch by MOR. The
transient nature of this acute altered coupling suggests that in
recycling, the receptor eventually recovers and couples to its
native G protein. We hypothesize that with chronic opioid
exposure, the receptor loses the ability to recover and continues
to couple to Gs, activating the adenylyl cyclase/cAMP pathway,
upregulating protein kinase A, and phosphorylating CREB as
one downstream effector example. The persistently elevated
phosphorylated CREB may then shape the expression of
responsive genes including those closely related to drug addiction
or withdrawal, such as brain-derived neurotrophic factor
(BDNF)[27], and tolerance. Importantly, the equivalent block-
ade of Gs coupling and pS
133CREB by the NLX and NTX
pentapeptide binding site on FLNA further elucidates the
mechanism of action of ultra-low-dose NLX and NTX in their
varied effects. These data strengthen our hypothesis that a
particular MOR–FLNA interaction allows MOR to couple to Gs
and that disrupting this interaction, either by NLX/NTX
b i n d i n gt oF L N Ao rv i aaF L N Ap e p t i d eb i n d i n gt oM O R
and/or FLNA, can prevent the altered coupling and attenuate
tolerance, dependence and addictive properties associated with
opioid drugs.
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Figure 7. The VAKGL pentapeptide binds both MOR and FLNA
proteins. To assess the mechanism whereby FLNA2561–2565 pentapep-
tide (VAKGL) disrupts the MOR–Gs coupling, cAMP accumulation and
CREB activation in a manner similar to 100 pM NLX or NTX, purified
MOR and FLNA proteins were tested for binding to streptavidin-coated
plates coated with biotinated VAKGL peptide. Both proteins, purified
from two different sources, showed marked binding to the peptide,
regardless of the peptide’s orientation on the plate. The bound proteins
were visualized with specific antibodies followed by FITC-conjugated
secondary antibodies, and the background FITC signal from matched
wells was subtracted from the total signal. n=12.
doi:10.1371/journal.pone.0004282.g007
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